Rhythm Biosciences Limited · ASX:RHY
Rhythm Biosciences — Non-Deal Roadshow (June 2025)
17 slides from Rhythm Biosciences's roadshow presentation, Jun 2, 2025
Slide 1: Investor Roadshow Presentation
For personal use only Investor Roadshow Presentation 2ND – 5TH JUNE 2025
Slide 2: Disclaimer
Disclaimer For personal use only This presentation has been prepared by Rhythm Biosciences Limited (Rhythm) and is provided for general information purposes only. No party other than Rhythm has authorised or caused the issue of this document, or takes responsibility for, or makes any statements, rep
Slide 3: About Rhythm Biosciences
About Rhythm Biosciences We are committed to Early detection of cancer gives individuals the best possible opportunity For personal use only for favorable treatment outcomes. saving lives through the evaluation of cancer risk Addressing large under-served global markets worth >USD$50bn and heavily s
Slide 4: Corporate overview
Corporate overview CORPORATE SNAPSHOT SHARE PRICE CHART - ASX:RHY For personal use only ASX Code RHY 2 Share Price (29th May 2025) $0.065 1.5 Shares on Issue 283,597M 1 Unlisted & Listed Options 53.4M Market Capitalisation $18.43M 0.5 Cash in Bank (31 March 2025) $2.3M 0 Top 20 Shareholders 43.3% 30
Slide 5: Cancer is an increasing burden on global healthcare systems
Cancer is an increasing burden on global healthcare systems The role of cancer diagnostics remains critical to public health Estimated % rise in all cancers Estimated number of worldwide 2022 to 2050 prevalent cases in 5 years from 2022 For personal use only Males and Females, Age 0-85+ Incidence: 8
Slide 6: When diagnosed early, cancer can be successfully treated
When diagnosed early, cancer can be successfully treated Disease stage for colorectal cancer diagnosis is the key predictor of survival Diagnoses at Stage I or II only represent less than half of all CRCs diagnosed in: For personal use only Missed detection of early-stage CRC results in poor surviva
Slide 7: The Cancer Patient Journey
The Cancer Patient Journey Multiple Diagnostic decisions support an individual through the patient journey P a For personal use only t i e n t MONITORING & J MINIMAL RESIDUAL RISK ASSESSMENT o DISEASE DETECTION u r n e y Surveillance PHARMA- COGENOMICS Detection & DRUG SCREENING SELECTION PHASES Dru
Slide 8: Multiomics: Proteins and Genes
Multiomics: Proteins and Genes Rhythm Biosciences has both a genomic and proteomic platform Cancer is a complex disease that is typified by For personal use only continuous change in cellular DNA, RNA (genome) and proteins (proteome). The genome and proteome contain some non- overlapping information
Slide 9: Detecting cancer earlier and maintaining wellness
Detecting cancer earlier and maintaining wellness The power of the combination of the Rhythm capabilities and portfolio For personal use only Y N E R U O J Risk Assessment Disease Screening MONITORING AND MINIMAL RESIDUAL T RISK ASSESSMENT DISEASE DETECTION Determination Minimally-invasive detection
Slide 10: Our portfolio accesses different biology using similar products
Our portfolio accesses different biology using similar products Rhythm products are engineered for affordable quality For personal use only Risk Assessment Disease Screening Product Format Reagent kits/service Reagent kit/service Patient Sample Cheek swab Blood What we measure DNA variation and clin
Slide 11: Rhythm portfolio launch and development schedule
Rhythm portfolio launch and development schedule A diversified mix of development stages and underlying technologies will drive value For personal use only Breast geneTypeTM Prostate geneTypeTM CRC geneTypeTM Additional Melanoma geneTypeTM geneTypeTM Pancreatic geneTypeTM Additional Additional Addit
Slide 12: Rhythm is targeting a significant global market
Rhythm is targeting a significant global market A global market of >0.5bn individuals potentially served by the Rhythm product platform. Genomic Platform: geneTypeTM Proteomic Platform: ColoSTAT® & Lung Cancer Screening For personal use only Unscreened high risk for Unscreened CRC Healthy CRC cancer
Slide 13: Our combined platforms supports a highly comprehensive approach to cancer diagnostics
Our combined platforms supports a highly comprehensive approach to cancer diagnostics The potential RHY product portfolio addresses a huge total available market For personal use only E Y R N U O J T MONITORING AND RISK MINIMAL RESIDUAL N ASSESSMENT DISEASE DETECTION E Risk Assessment • • • • • • •
Slide 14: Upcoming value inflection points
Upcoming value inflection points For personal use only PRODUCT ITEM DESCRIPTION COMPLETION DATE ColoSTAT® Kit Validation Ready Kit Verification completion, production kits ready Q2 CY 2025 ColoSTAT® Independent clinical validation Evaluation of final kit on independent clinical samples Q3 CY 2025 ge
Slide 15: Rhythm Bioscience: An attractive investment opportunity
Rhythm Bioscience: An attractive investment opportunity For personal use only Overview Growth Reasons to Invest Rhythm’s mission is to 1. Multi-product portfolio detect cancer earlier and Rhythm is solving an reduce the burden of important clinical and 2. Addressing a significant TAM cancer. We are
Slide 16: Recent ASX market updates
Recent ASX market updates RHY recent ASX announcements – direct to asx.com.au Date Announcement Link For personal use only 26-May-25 ColoSTAT® Beta kit verification and validation ASX Link 15-May-25 Breast Cancer Risk Study University of Melbourne ASX Link 24-Apr-25 Quarterly Activities Report and A
Slide 17: Thank you!
For personal use only Thank you! david.atkins@rhythmbio.com www.rhythmbio.com